

Golodirsen (Vyondys 53™)

Place of Service

Infusion Center Administration

Home Infusion Administration

Office Administration

Outpatient Facility Infusion Administration

Hospital Outpatient Facility

Administration\* [\*Prior authorization required – see section (1)]

HCPCS: J1429 per 10 mg

Condition listed in policy (see criteria for details)

- [Duchenne muscular dystrophy \(DMD\)](#)

**AHFS therapeutic class:** Genetic disorder treatment; antisense oligonucleotide

**Mechanism of action:** antisense oligonucleotide that binds to exon 53 of dystrophin pre-mRNA resulting in exon exclusion to produce truncated dystrophin protein in patients with genetic mutations that are amenable to exon 53 skipping.

**(1) Special Instructions and Pertinent Information**

**Covered under the medical benefit,** please submit clinical information for prior authorization review via fax.

**\*\*CRITERIA FOR HOSPITAL OUTPATIENT FACILITY ADMINISTRATION \*\***

*AAAAI Guidelines 2011, MCG™ Care Guidelines, 19th edition, 2015*

Members with the following plans: **PPO, Direct Contract HMO, and when applicable, ASO/Shared Advantage/HMO (non-direct contract)** may be required to have their medication administered at a preferred site of service, including the home, a physician's office, or an independent infusion center not associated with a hospital.

For members that cannot receive infusions in the preferred home or ambulatory setting AND meet one of the following criteria points, drug administration may be performed at a hospital outpatient facility infusion center.

**ADMINISTRATION OF VYONDYS 53™ IN THE HOSPITAL OUTPATIENT FACILITY SITE OF CARE REQUIRES ONE OF THE FOLLOWING: (Supporting Documentation must be submitted)**

1. Patient is receiving their first injection of Vyondys 53 or is being re-initiated on Vyondys 53 after at least 6 months off therapy. *Subsequent doses will require medical necessity for continued use in the hospital outpatient facility site of care.*

Additional clinical monitoring is required during administration as evidenced by one of the following:

2. Patient has experienced a previous severe adverse event to Vyondys 53™ based on documentation submitted.
3. Patient continues to experience moderate to severe adverse events to Vyondys 53™ based on documentation submitted, despite receiving premedication such as acetaminophen, steroids, diphenhydramine, fluids, etc.
4. Patient is clinically unstable based on documentation submitted.

5. Patient is physically or cognitively unstable based on documentation submitted.

**(2) Prior Authorization/Medical Review is required for the following condition(s)**

All requests for Vyondys 53™ (golodirsen) must be sent for clinical review and receive authorization prior to drug administration or claim payment.

**Duchenne muscular dystrophy (DMD)**

1. Prescribed by or in consultation with a pediatric neurologist or neuromuscular specialist, **AND**
2. Diagnosis of DMD that is amenable to exon 53 skipping confirmed by genetic testing

**Covered Dose**

Up to 30 mg/kg IV every week

**Coverage Period**

Indefinitely

**ICD-10:**

G71.01

**(3) The following condition(s) DO NOT require Prior Authorization/Preservice**

All requests for Vyondys 53® (golodirsen) must be sent for clinical review and receive authorization prior to drug administration or claim payment.

**(4) This Medication is NOT medically necessary for the following condition(s)**

Coverage for a Non-FDA approved indication, requires that criteria outlined in Health and Safety Code § 1367.21, including objective evidence of efficacy and safety are met for the proposed indication.

Please refer to the Provider Manual and User Guide for more information.

**(5) Additional Information**

How Supplied:

- 100 mg/2 mL (single-dose vial)

**(6) References**

- AHFS®. Available by subscription at <http://www.lexi.com>
- DrugDex®. Available by subscription at <http://www.micromedexsolutions.com/home/dispatch>
- Vyondys 53™ (golodirsen) [Prescribing information]. Cambridge, MA: Sarepta Therapeutics Inc.; 2/2021.

**(7) Policy Update**

Date of last review: 2Q2023

Date of next review: 2Q2024

Changes from previous policy version:

- No change to policy following routine annual review.

*BSC Drug Coverage Criteria to Determine Medical Necessity  
Reviewed by P&T Committee*

PHP Medi-Cal

Golodirsen (Vyondys 53™)

Effective: 03/29/2023

Page 2 of 2